Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aussie Study Warns Ibuprofen, Codeine Combos Can Be Addictive (Australia)

This article was originally published in PharmAsia News

Executive Summary

Australian researchers are raising an alarm about the possibility that popular painkillers in the country can become addictive and cause other health problems. The doctors said in their published study they are concerned about overuse of codeine- and ibuprofen-containing drugs. The head of Australia's Pharmacy Guild says codeine is a common ingredient in many drugs. Long-term use of ibuprofen products in large amounts is known to cause liver damage and heart problems, but the study said many ibuprofen drugs also contain codeine, so they also can become addictive. (Click here for more

You may also be interested in...



More Heartmate Troubles For Abbott. Latest Recall Includes 14 Deaths

Abbott initiated a recall in February of thousands of Heartmate devices due to a system obstruction that can result in serious health outcomes, including death. The FDA has now designated the recall as class I.

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

As it stands, drugmakers will have just 90 days to prepare their dossiers for EU-wide joint clinical assessments under the new Health Technology Assessment Regulation. Market access experts from EFPIA tell the Pink Sheet that this short deadline could delay patient access to complex medicines, such as innovative cancer drugs.

National Drug Stockpiles Create ‘False Sense Of Security’

The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066570

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel